ITMCTR2000003138Recruiting未知
Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period
Hu'nan Cancer Hospital0 sitesStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •(1) aged 18-60 years;
- •(2) BMI in the normal range (1+/-20%);
- •(3) diagnosis of lung cancer, breast cancer, cervical cancer, colorectal cancer, with surgical indications, no distant metastasis;
- •(4) ASA grade I-II;
- •(5) no thymosin A1, Chinese Medicine (Bazhen Tang) use contraindications;
- •(6) before the test, the patients or their legal representatives understand and voluntarily sign the ethics Informed consent approved by the Committee.
Exclusion Criteria
- •(1) had participated in other clinical trials within 4 weeks before the start of this study;
- •(2) used albumin and immunoenhancer drugs within 15 days before operation;
- •(3) had a history of coronavirus infection, direct or indirect exposure, had fever, cough;
- •(4) had previous immune deficiency;
- •(5) had congenital metabolic abnormalities and other diseases;
- •(6) Patients with autoimmune diseases and infections;
- •(7) pregnant and lactating women;
- •(8) who were not willing to participate in the study for any reason.
Investigators
Similar Trials
Completed
Not Applicable
Perioperative Immune Function and Clinical Complications in PancreaduodenectomyPancreas CancerNCT04774198Rigshospitalet, Denmark58
Active, not recruiting
Phase 1
Peri-operative association of immunotherapy in oeso-gastric adenocarcinomaEUCTR2018-004712-22-FRGERCOR32
Recruiting
Not Applicable
Immunity in Perioperative Practicecardia and esophagus cancer)upper gastrointestinal cancer (stomach10027656NL-OMON53931niversitair Medisch Centrum Utrecht98
Active, not recruiting
Phase 1
PIONEER is a clinical study in patients with squamous cell carcinoma of the head and neck that is amenable to surgical resection with curative intent. This study will determine the feasibility of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®)local squamous cell carcinoma of the head and neckMedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000254-21-DEniversity Hospital Essen40
Completed
Not Applicable
Clinical analysis of preoperative immune-nutritional support for lung cancer patientsPreoperative lung cancer patientsJPRN-UMIN000035851Kyushu Medical Center40